About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Phoenix | 16,646 Studies Near You | Clareo Health

Clinical Trials LocationsPhoenix

Clinical Trials in Phoenix

Discover 16,646 clinical trials near Phoenix, Arizona. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 16381-16400 of 16,646 trials

COMPLETEDPhase 1< 1 mile

Study Evaluating Single Doses of PPM-204 on the Electrical Pathways of the Heart

NCT00447629

A study evaluating the safety of a high and low dose of PPM-204 on the electrical pathways of the heart.

Diabetes Mellitus

Wyeth is now a wholly owned subsidiary of PfizerStarted Jan 2007

Phoenix, Arizona, United States

TERMINATEDPhase 2/3< 1 mile

Study Evaluating the Efficacy of DVS-233 in Fibromyalgia

NCT00301431

The purpose of this study is to determine if DVS-233 is safe and effective in the treatment of pain and other symptoms of fibromyalgia syndrome.

Wyeth is now a wholly owned subsidiary of Pfizer1,050 participantsStarted Aug 2006

Huntsville, Alabama, United States • Mobile, Alabama, United States • Phoenix, Arizona, United States +56 more locations

Find Trials by Condition in Phoenix

Breast Cancerin Phoenix Lung Cancerin Phoenix Prostate Cancerin Phoenix Colorectal Cancerin Phoenix Melanomain Phoenix Leukemiain Phoenix Lymphomain Phoenix Pancreatic Cancerin Phoenix Ovarian Cancerin Phoenix Brain Cancerin Phoenix Diabetes

Data from ClinicalTrials.govTerms

UNKNOWN< 1 mile

Prospective Study to Identify Patients at Risk of Dangerous Ventricular Arrhythmias

NCT00562757

The purpose of this study is to determine how well the device predicts susceptability to potentially lethal ventricular arrhythmias.

Sudden Cardiac Death

Harbinger Medical, Inc.320 participantsStarted Sep 2003

Phoenix, Arizona, United States • Wichita, Kansas, United States • Boston, Massachusetts, United States +5 more locations

COMPLETEDPhase 1< 1 mile

Gene Therapy to Improve Wound Healing in Patients With Diabetes

NCT00065663

Patients with diabetes may develop chronic wounds that respond poorly to treatment. Gene therapy with the platelet-derived growth factor-B gene has been shown to help with the healing of chronic wounds. This study will evaluate a new way to deliver the gene to the wound tissue.

Wounds and InjuriesDiabetesDiabetic Foot Ulcers+1 more

Tissue Repair Company21 participantsStarted Aug 2002

Phoenix, Arizona, United States • San Diego, California, United States

SUSPENDEDPhase 3< 1 mile

Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis

NCT00460967

SUMMARY Age-related macular degeneration (AMD) is the leading cause of late onset visual impairment and legal blindness in people 65 years of age or older in the United States. It is a heterogeneous clinical entity in which retinal degeneration occurs predominantly in the macula in the context of aging and leads to impairment primarily of central visual acuity. The degenerative retinal eye disease occurs in two forms - a non-exudative "dry" form and an exudative "wet" form which in an individual patient may also represent stages of the disease. Non-exudative AMD accounts for 80-90% of AMD cases and it involves a constellation of clinical features that can include drusen, pigment clumping and/or retinal pigment epithelium (RPE) dropout, and geographic atrophy. Because of the overwhelming numbers of "dry" AMD subjects, the cumulative impact of this vision loss is significant. There is no effective therapy for maintaining or improving vision associated with dry AMD. The only therapy for persons with dry AMD is an oral supplement containing high doses of antioxidants and zinc, which was tested by the National Eye Institute in a large, multi-center, double-masked, sham-controlled clinical trial1. This antioxidant therapy was shown to modestly retard the progression of dry AMD from an intermediate stage to the advanced stages and confirmed the benefit of antioxidant therapy in this disease. There is currently no FDA-approved therapy for the treatment of subjects with dry AMD. Recently, the MIRA-1 modified per protocol population showed the effectiveness of Rheopheresis which is an application of selective therapeutic apheresis, namely double filtration plasmapheresis (DFPP) using a specifically designed filter for plasma filtration in subjects with non-exudative AMD. At one year the study reported with statistical significance (1) approximately a one line vision improvement in the Rheopheresis group versus no change in the Sham group and (2) 28% of subjects randomized to the active treatment gaining at least one line vision versus only 9% of subjects randomized to the sham treatment. With a total of 300 subjects with dry AMD and visual acuity of 20/40-20/100 inclusive, the current investigation plans to prove the effectiveness of the Rheopheresis treatment on a larger scale. Each subject will receive a series of 8 treatments (either active treatment or sham treatment in a 2:1 ratio) for a period of approximately 2.5 months. In addition, a post-treatment ophthalmic evaluation will be performed 2 weeks after the 8th treatment (approximately 3 months after the baseline visit) and at the 6, 9 and 12 month visits. Comparing the one-year proportions of at least a 10-letter gain in ETDRS LogMar BCVA from baseline, the current investigation will show the effectiveness of Rheopheresis treatment (compared to sham treatment) for treating dry AMD subjects. Other secondary effectiveness endpoints, including mean changes and proportions of BCVA better than 20/40 at one year, will be analyzed to support the main investigation.

Age-Related Maculopathy

OccuLogix325 participantsStarted Jan 2007

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +36 more locations

TERMINATEDPhase 3< 1 mile

DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])

NCT00273338

The primary objective of this study is: * To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on survival in metastatic androgen-independent prostate cancer The secondary objectives of this study are: * To determine the effect of the ASCENT regimen on the rate of thromboembolic events (blood clots) * To determine the effect of the ASCENT regimen on prevention of skeletal-related events (fractures) * A Separate sub-study will be conducted at selected study sites in North America to determine the population PK of DN-101.

Prostate Cancer

Novacea1,200 participantsStarted Jan 2006

Birmingham, Alabama, United States • Muscle Shoals, Alabama, United States • Anchorage, Alaska, United States +219 more locations

COMPLETEDPhase 3< 1 mile

Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome

NCT00190866

To assess the efficacy of Duloxetine compared with placebo in the treatment of pain in patients with Fibromyalgia syndrome, with or without major depressive disorder.

Eli Lilly and Company210 participantsStarted Jun 2005

Peoria, Arizona, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +32 more locations

COMPLETEDPhase 318 miles

Amphotericin B Suspension in Refractory Chronic Sinusitis

NCT00425620

The primary objective of the study is to evaluate the safety and efficacy of Amphotericin B suspension versus placebo in the complete resolution of key chronic sinusitis symptoms during 16 weeks of treatment in patients with refractory, postsurgical CS.

Chronic Sinusitis

Accentia Biopharmaceuticals300 participantsStarted Dec 2006

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Gilbert, Arizona, United States +65 more locations

UNKNOWNPhase 2108 miles

Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma

NCT00383851

This is a multicenter, randomized, phase II study to evaluate the safety and efficacy of oral ATN-224 plus temozolomide in patients with advanced melanoma. Patients will be randomized (1:1) between temozolomide and ATN-224 and temozolomide followed by ATN-224. Patients assigned to the sequential treatment group will receive temozolomide until progression of disease is documented and then receive ATN-224 as a single agent until documentation of progression of disease using the last tumor assessment on temozolomide therapy as the baseline assessment.

Attenuon60 participantsStarted Sep 2006

Tucson, Arizona, United States • Encinitas, California, United States • Orange, California, United States +14 more locations

COMPLETEDPhase 3108 miles

Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis

NCT00049764

The purposes of this study are to determine: 1. Whether drotrecogin alfa (activated) helps children with severe sepsis survive their condition more often or recover faster than children who do not receive drotrecogin alfa (activated). 2. Whether drotrecogin alfa (activated) minimizes long term disabilities associated with severe sepsis. 3. The side effects that might be associated with drotrecogin alfa (activated) administration to children with severe sepsis.

Eli Lilly and Company474 participantsStarted Nov 2002

Birmingham, Alabama, United States • Tucson, Arizona, United States • Tuscon, Arizona, United States +46 more locations

COMPLETEDPhase 4207 miles

Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse

NCT00190957

Atomoxetine Treatment of Adults with ADHD and Comorbid Alcohol Abuse

ADHDComorbid Alcohol Abuse

Eli Lilly and Company140 participantsStarted Aug 2004

El Centro, California, United States • Poway, California, United States • San Diego, California, United States +12 more locations

UNKNOWNPhase 3244 miles

Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.

NCT00337389

To compare the progression-free survival time (PFS) in patients treated with 5-FU modulated with CoFactor (plus bevacizumab) to 5-FU modulated with leucovorin (plus bevacizumab) in patients with Metastatic Colorectal Cancer.

Metastatic Colorectal CancerColon CancerRectal Cancer

Mast Therapeutics, Inc.1,200 participantsStarted May 2006

Florence, Alabama, United States • Anaheim, California, United States • Apple Valley, California, United States +44 more locations

COMPLETEDPhase 4289 miles

Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)

NCT00190736

A study to compare the effect of once-daily atomoxetine versus placebo in treating symptoms of ADHD in adults for up to 6 months.

Eli Lilly and Company440 participantsStarted Sep 2004

Lafayette, California, United States • Spring Valley, California, United States • Farmington, Connecticut, United States +16 more locations

COMPLETEDPhase 4290 miles

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

NCT00090012

The purposes of this study are to determine: * The effectiveness of olanzapine as compared to quetiapine in treating and preventing the recurrence of a variety of symptoms of schizophrenia and schizoaffective disorder in patients who are obese or overweight. * The safety of olanzapine as compared to quetiapine.

SchizophreniaSchizoaffective Disorder

Eli Lilly and Company340 participantsStarted Jul 2004

Garden Grove, California, United States • La Mesa, California, United States • San Diego, California, United States +22 more locations

COMPLETEDPhase 3290 miles

A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder

NCT00122850

This study will examine duloxetine compared with placebo and an active comparator in the treatment of generalized anxiety disorder.

Anxiety Disorders

Eli Lilly and Company480 participantsStarted Oct 2004

Birmingham, Alabama, United States • La Mesa, California, United States • Denver, Colorado, United States +16 more locations

COMPLETEDPhase 2357 miles

A Study of ABT-751 in Patients With Colorectal Cancer

NCT00073138

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with colorectal cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

Colorectal Cancer

Abbott40 participantsStarted Aug 2003

Los Angeles, California, United States • Santa Monica, California, United States • Chicago, Illinois, United States +3 more locations

TERMINATEDPhase 3366 miles

A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration

NCT00139282

Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of blindness among adults age 50 or older in the Western world. AMD presents in two different types: "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula. Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will evaluate the safety and efficacy of Squalamine lactate in the treatment of AMD in patients, the exact number of which will be determined based on data from the sponsor's ongoing Phase 2 trials. The trial objective is to evaluate the safety and efficacy of two doses of Squalamine lactate for Injection administered as intravenous infusions weekly for 4 weeks followed by maintenance doses every 4 weeks through week 104 compared with the safety and efficacy in the control group.

"Wet" Age-Related Macular Degeneration

Genaera CorporationStarted Jun 2005

Beverly Hills, California, United States • Louisville, Colorado, United States • Boynton Beach, Florida, United States +26 more locations

TERMINATEDPhase 2411 miles

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

NCT00120198

Currently there is no one standard of care for older patients with Non-Hodgkin's Lymphoma (NHL). The study will examine the tolerability and feasibility to the combination of Cyclophosphamide, Pegylated Liposomal Doxorubicin, Vincristine, Prednisone (CDOP) plus Rituximab.

Non-Hodgkin's Lymphoma

Geriatric Oncology Consortium50 participantsStarted Mar 2005

Oxnard, California, United States • Washington D.C., District of Columbia, United States • Inverness, Florida, United States +2 more locations

TERMINATEDPhase 2486 miles

Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer

NCT00120172

Currently there is no one standard of care for older patients with metastatic colorectal cancer. The study will examine the tumor response to capecitabine, oxaliplatin, plus bevacizumab. The study will also gather information on the usefulness and side effects of this treatment combination.

Colorectal CancerNeoplasm Metastasis

Geriatric Oncology Consortium40 participantsStarted May 2005

Mission Hills, California, United States • Washington D.C., District of Columbia, United States • Inverness, Florida, United States +2 more locations

COMPLETEDPhase 2631 miles

Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression

NCT00322764

The primary purpose of this study is to determine the safety and efficacy of oral RG2417 (Uridine) when administered to patients with Bipolar I depression twice daily for six weeks.

Bipolar Depression

Repligen Corporation80 participantsStarted Mar 2006

Stanford, California, United States • Smyrna, Georgia, United States • Indianapolis, Indiana, United States +8 more locations

PreviousPage 820 of 833Next

in Phoenix

Heart Diseasein Phoenix